Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,820 total articles
AMN Healthcare Services (AMN) looks attractively priced on free cash flow and EV/EBITDA despite negative earnings and elevated leverage. Management expects a recovery in travel and allied staffing demand; combine that with a Technology & Workforce push and a still-low P/S and the stock offers an asymmetric reward-to-risk profile for a mid-term trad…
Pinterest is trading near its 52-week low after a brief sell-off tied to a restructuring announcement. With a clean balance sheet, strong cash generation and a pivot toward AI-driven visual shopping and connected TV ads, the setup offers meaningful upside vs. limited downside. I lay out an actionable entry, stop and target with catalysts and specif…
CoStar Group's combination of aggressive buybacks, 2026 profit targets and an activist nudge from Third Point make the stock a tactical long. Valuation remains rich, but with a clear catalyst runway and a favorable risk/reward, we upgrade to a buy and lay out an actionable trade with defined entry, stop and target for a mid-term swing (45 trading d…
Pinterest is cheap on traditional metrics, trading near $23 with a sub-8x P/E, strong free cash flow and zero debt. Management's pivot to AI and connected-TV advertising (post-tvScientific) creates a clear monetization runway. Enter a long, defined-risk trade targeting a return to mid‑cycle multiples while watching execution risks tied to restructu…
Churchill Capital Corp IX (CCIX) is a blank-check vehicle trading at $10.67 with a market cap of roughly $391M. This trade idea takes a tactical long into expected merger-related momentum around an AI trucking target: entry at $10.67, stop at $10.15, target $12.50, mid-term horizon (45 trading days). The setup mixes tight technicals, low float rela…
CareCloud is a cloud-native EHR and practice management provider that has pivoted into AI-driven workflows. At roughly $122M market cap and a free cash flow yield approaching 18%, the stock looks cheap relative to its cash generation and EV/EBITDA of 4.8. This trade idea targets a measured long with a clear entry, stop and target and a 180-trading-…
Chubb trades like a high-quality insurer at a reasonable price: double-digit ROE, P/E near 12, and a 52-week range that still leaves room above current levels. I lay out a mid-term (45 trading days) swing trade to capture an 8% move toward $328 while limiting downside with a $292 stop. The thesis balances stable underwriting performance and balance…
FLEX LNG (FLNG) trades at about $26.53 and yields ~11.3% from consistent $0.75 quarterly distributions. With a market cap near $1.43B, a modest P/B and P/E, and steady charter-driven cash flow, the stock offers an asymmetric income-first trade. I outline an entry, stop, and target for a 180-trading-day hold and the key catalysts and risks to watch.
Warrior Met Coal (HCC) trades at elevated multiples but sits on a large cash cushion and low leverage. If Blue Creek meaningfully lowers unit costs and boosts production, the company can convert its cash cushion into positive free cash flow and justify a return toward its 52-week highs. This trade idea outlines an actionable long with entry, stop, …
UnitedHealth (UNH) is a structurally advantaged insurer and healthcare services platform that just got cheaper after a policy surprise and disappointing top-line guidance. Fundamentals still show strong free cash flow, a reasonable valuation and operating leverage through Optum. This trade buys the dip with a defined stop and a 180 trading-day targ…
Boston Beer is down materially from its 52-week high but still generates healthy free cash flow, carries no debt, and trades at a reasonable multiple versus its cash generation. This trade plan targets a recovery to near prior highs while protecting capital with a tight stop and staged profit-taking across a 180-day horizon.
AngloGold Ashanti has become the cleanest way to play the recent gold rally: production growth, record free cash flow, and strategic M&A have pushed the stock to a new 52-week high. The technicals show bullish momentum but also an overbought short-term reading. This trade idea buys strength with a disciplined stop at $98 and a mid-term target of $1…
Urban Outfitters (URBN) combines a debt-free balance sheet, $402.7M in free cash flow and accelerating brand performance into a tradeable long: entry $69.61, target $82.00, stop $62.00. Valuation is reasonable (P/E ~13, EV/EBITDA ~8.5) and the stock trades well below this cycle's highs, leaving room for a re-rate if top-line momentum and subscripti…
Meta surged after Q4 strength and looks set to extend gains as AI tailwinds roll through its ad and infrastructure businesses. Valuation is reasonable given free cash flow strength and low leverage. This trade plan targets $900 over the next 180 trading days with a strict stop at $640 to respect the technical picture and protect against macro-drive…
VEON offers an asymmetric risk-reward: Kyivstar’s operational wins (Starlink Direct-to-Cell scale, solar acquisition) and other regional growth initiatives justify a long trade at current levels given a P/E near 6 and a $3.73B market cap. Actionable plan included.
Willdan Group (WLDN) sits squarely in the grid-modernization theme: technical consulting for utilities plus civil engineering services. Strong free cash flow, low leverage, and bullish technicals argue for a tactical long. Valuation is rich, so position sizing and a tight stop are essential.
Hess Midstream combines recurring fee-based midstream cash flows with an equity yield north of 8% and valuation metrics that look compressed versus its cash generation. Given an improving technical backdrop and upcoming dividend pay dates, we see a pragmatic long trade with defined risk: enter at $36.00, target the prior 52-week high at $44.14, sto…
Sportradar is a market leader in sports data and betting technology with accelerating margins, a string of strategic deals (IMG ARENA, Bundesliga expansion), active buybacks and a current technical oversold setup. At a market cap of ~$5.8B and rich but justifiable growth expectations, I view SRAD as a long-term trade for investors willing to tolera…
AerCap (AER) looks attractively priced for 2026: market cap roughly $25.2B, a trailing P/E near 6.6, and a recovery from the 2025 low leaves room to run. We lay out an actionable long trade with entry, stop, and target, review the fundamentals that matter for lessors, and spell out the risks that would invalidate the thesis.
Hercules Capital (HTGC) offers an 8%-9% yield, a modest P/E near 11 and a P/B around 1.5. For income-seeking investors who can tolerate credit and rate volatility, HTGC presents a balanced long trade: collect a high dividend while holding for potential capital appreciation as credit performance and rate expectations normalize.
Tencent is set to benefit from Beijing's renewed emphasis on domestic tech services and a looser stance on high-end AI chip imports. At a $717B market cap and a P/E of ~23.5, Tencent offers a blend of growth (cloud, FinTech, games) and cash flow stability. We favor a long trade with a clear entry, stop and target tied to observable technical and po…
Chemours (CC) looks set to re-rate in 2026 as tight supply for high-purity hydrofluoroethers, steady demand for Opteon refrigerants, and improving technical momentum combine with a cheap starting valuation versus enterprise value. We present a long trade with entry at $15.10, stop at $13.00 and a $22.00 target over a 46-180 trading day time frame.
Cullinan Therapeutics (CGEM) is a clinical-stage oncology and immuno-immunology developer trading at roughly $700M market cap while sitting on a substantial cash reserve. With CLN-978 advancing toward clinical readouts, a positive zipalertinib trajectory and a reported cash runway into 2028, Cullinan offers an asymmetric long opportunity: the marke…
General Mills is trading like a broken consumer staples play despite healthy cash flow, a double-digit return on equity, and a 5%+ dividend yield. This trade idea lays out a swing trade to take advantage of excessive pessimism while keeping tight risk controls below recent support.
Exelixis (EXEL) is a profitable oncology company trading near $42.67 with solid free cash flow, low leverage and a pipeline catalyst in zanzalintinib. A favorable FDA outcome could push the stock toward the mid-$40s to $50s; the trade below balances upside with a clear stop and a mid-term time horizon tied to a likely near-term regulatory event.
